Diagnosis (Laboratory other parameters)
K (→host genetics) |
|||
| (7 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| − | + | __NOTOC__ | |
| + | |||
| + | ===any=== | ||
| + | {{tp|p=32475810|t=2020. The role of biomarkers in diagnosis of COVID-19 - A systematic review.|pdf=|usr=007}} | ||
| + | {{tp|p=32259132|t=2020. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study |pdf=|usr=}} | ||
| + | {{tp|p=32360478|t=2020. Emerging key laboratory tests for patients with COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32371192|t=ä. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus |pdf=|usr=}} | ||
| + | {{tp|p=32344011|t=2020. Mild versus severe COVID-19: Laboratory markers |pdf=|usr=}} | ||
| + | {{tp|p=32341519|t=ä. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia |pdf=|usr=}} | ||
| + | {{tp|p=32301748|t=2020. Clinical chemistry tests for patients with COVID-19 - important caveats for interpretation |pdf=|usr=}} | ||
| + | {{tp|p=32526372|t=2020. Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests.|pdf=|usr=008}} | ||
| + | {{tp|p=32425643|t=2020. Association of inflammatory markers with the severity of COVID-19: A meta-analysis.|pdf=|usr=008}} | ||
| + | {{tp|p=32519779|t=2020. Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms.|pdf=|usr=008}} | ||
| + | {{tp|p=32471703|t=2020. Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.|pdf=|usr=008}} | ||
| + | {{tp|p=32492406|t=2020. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.|pdf=|usr=008}} | ||
| + | |||
| + | |||
| + | ===Hypoxia=== | ||
| + | {{tp|p=32471783|t=2020. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.|pdf=|usr=008}} | ||
| + | |||
| + | |||
| + | ===Glucose=== | ||
{{tp|p=32360710|t=2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes |pdf=|usr=}} | {{tp|p=32360710|t=2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes |pdf=|usr=}} | ||
| + | {{tp|p=32515386|t=2020. Glucovigilance in COVID-19.|pdf=|usr=008}} | ||
| − | + | ||
| + | ===Presepsin=== | ||
{{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}} | {{tp|p=32333860|t=2020. Presepsin in risk stratification of SARS-CoV-2 patients |pdf=|usr=}} | ||
| + | {{tp|p=32530491|t=2020. Presepsin as a predictive biomarker of severity in COVID-19: A case series.|pdf=|usr=008}} | ||
| + | |||
| + | |||
| − | + | ===Procalcitonin=== | |
{{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | ||
| + | {{tp|p=32414743|t=2020. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32534186|t=2020. Procalcitonin levels in COVID-19 patients.|pdf=|usr=008}} | ||
| − | + | ===SAA serum amyloid a=== | |
{{tp|p=32277967|t=ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32277967|t=ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}} | ||
| − | + | ===suPAR=== | |
{{tp|p=32354367|t=2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia |pdf=|usr=}} | {{tp|p=32354367|t=2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia |pdf=|usr=}} | ||
| − | + | ===Fever=== | |
| + | {{tp|p=32503659|t=2020. Body temperature correlates with mortality in COVID-19 patients.|pdf=|usr=007}} | ||
| + | {{tp|p=32417316|t=2020. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32519768|t=2020. Hyperpyrexia in COVID-19 patients.|pdf=|usr=008}} | ||
| + | |||
| + | ===ESR BKS BSG=== | ||
| + | {{tp|p=32386190|t=2020. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis.|pdf=|usr=007}} | ||
| + | |||
| + | ===CRP=== | ||
{{tp|p=32368728|t=ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study |pdf=|usr=}} | {{tp|p=32368728|t=ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study |pdf=|usr=}} | ||
{{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | ||
{{tp|p=32281668|t=2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early |pdf=|usr=}} | {{tp|p=32281668|t=2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early |pdf=|usr=}} | ||
{{tp|p=32455147|t=ä. C reactive protein level may predict the risk of COVID-19 aggravation |pdf=|usr=}} | {{tp|p=32455147|t=ä. C reactive protein level may predict the risk of COVID-19 aggravation |pdf=|usr=}} | ||
| + | {{tp|p=32511972|t=2020. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection.|pdf=|usr=007}} | ||
| + | {{tp|p=32445579|t=2020. Prognostic value of C-reactive protein in patients with COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32425269|t=2020. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32516845|t=2020. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32414383|t=2020. Plasma CRP level is positively associated with the severity of COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32531257|t=2020. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32533986|t=2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=008}} | ||
| − | + | ===IL-6=== | |
{{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | {{tp|p=32344321|t=2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 |pdf=|usr=}} | ||
{{tp|p=32259560|t=ä. Interleukin-6 as a potential biomarker of COVID-19 progression |pdf=|usr=}} | {{tp|p=32259560|t=ä. Interleukin-6 as a potential biomarker of COVID-19 progression |pdf=|usr=}} | ||
{{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}} | {{tp|p=32414693|t=2020. Interleukin-6 levels in children developing SARS-CoV-2 infection |pdf=|usr=}} | ||
{{tp|p=32297995|t=2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients |pdf=|usr=}} | {{tp|p=32297995|t=2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients |pdf=|usr=}} | ||
| + | {{tp|p=32475230|t=2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.|pdf=|usr=007}} | ||
| + | {{tp|p=32428990|t=2020. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.|pdf=|usr=007}} | ||
| + | {{tp|p=32385523|t=2020. IL-6 may be a good biomarker for earlier detection of COVID-19 progression.|pdf=|usr=008}} | ||
| + | {{tp|p=32425269|t=2020. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32526326|t=2020. Interleukin-6 as prognosticator in patients with COVID-19.|pdf=|usr=008}} | ||
| − | + | ===IL-10=== | |
| + | {{tp|p=32475230|t=2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.|pdf=|usr=007}} | ||
| + | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}} | ||
| + | |||
| + | ===IL-1ra=== | ||
| + | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}} | ||
| + | |||
| + | ===Rantes=== | ||
| + | {{tp|p=32501293|t=2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.|pdf=|usr=007}} | ||
| + | |||
| + | ===NLratio=== | ||
{{tp|p=32283162|t=ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 |pdf=|usr=}} | {{tp|p=32283162|t=ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 |pdf=|usr=}} | ||
{{tp|p=32242828|t=2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan |pdf=|usr=}} | {{tp|p=32242828|t=2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan |pdf=|usr=}} | ||
| + | {{tp|p=32458459|t=2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.|pdf=|usr=007}} | ||
| + | {{tp|p=32304994|t=ä. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients |pdf=|usr=}} | ||
| + | {{tp|p=32503668|t=2020. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.|pdf=|usr=008}} | ||
| + | {{tp|p=32242950|t=2020. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.|pdf=|usr=008}} | ||
| + | {{tp|p=32533986|t=2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=008}} | ||
| − | ''' | + | {{tp|p=32531713|t=2020. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.|pdf=|usr=008}} |
| + | {{tp|p=32437920|t=2020. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line.|pdf=|usr=008}} | ||
| + | |||
| + | ===PLratio=== | ||
| + | {{tp|p=32181903|t=2020. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.|pdf=|usr=008}} | ||
| + | |||
| + | *'''[[Trombocytopenia|Thrombocytopenia]]''' | ||
| + | |||
| + | ===Troponin=== | ||
{{tp|p=32348472|t=ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?|pdf=|usr=}} | {{tp|p=32348472|t=ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?|pdf=|usr=}} | ||
| − | + | ===Eosinophils=== | |
{{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | {{ttp|p=32315429|t=ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
{{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | {{tp|p=32315421|t=ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19) |pdf=|usr=}} | ||
| − | + | ===IL2R on lymphcytes=== | |
{{tp|p=32365221|t=2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19 |pdf=|usr=}} | {{tp|p=32365221|t=2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19 |pdf=|usr=}} | ||
| − | + | ===Angiopoietin 2=== | |
| + | {{tp|p=32458111|t=2020. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.|pdf=|usr=008}} | ||
| + | |||
| + | ===microRNA=== | ||
| + | {{tp|p=32526370|t=2020. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?|pdf=|usr=008}} | ||
| + | |||
| + | ===tumor markers=== | ||
{{tp|p=32347972|t=2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19 |pdf=|usr=}} | {{tp|p=32347972|t=2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19 |pdf=|usr=}} | ||
| + | ===mda5 il-24=== | ||
| + | {{tp|p=32485313|t=2020. MDA5 should be detected in severe COVID-19 patients.|pdf=|usr=007}} | ||
| + | ===H2S=== | ||
| + | {{tp|p=32433216|t=2020. Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus.|pdf=|usr=007}} | ||
| − | + | ===ACE2=== | |
| + | {{tp|p=32283335|t=2020. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease.|pdf=|usr=008}} | ||
| + | |||
| + | ===trmpss2=== | ||
| + | {{tp|p=32437018|t=2020. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.|pdf=|usr=007}} | ||
| + | |||
| + | ===KL-6=== | ||
| + | {{tp|p=32470148|t=2020. Serum KL-6 concentrations as a novel biomarker of severe COVID-19.|pdf=|usr=007}} | ||
| + | |||
| + | ===monocyte distribution width=== | ||
| + | {{tp|p=32504637|t=2020. Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator.|pdf=|usr=007}} | ||
| + | |||
| + | ===Calcium=== | ||
| + | {{tp|p=32459190|t=2020. Low levels of total and ionized calcium in blood of COVID-19 patients.|pdf=|usr=007}} | ||
| + | {{tp|p=32533508|t=2020. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.|pdf=|usr=008}} | ||
| + | |||
| + | ===LDH=== | ||
| + | {{tp|p=32531257|t=2020. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.|pdf=|usr=008}} | ||
| + | |||
| + | ===Liver enzymes=== | ||
| + | {{tp|p=32525000|t=2020. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32526083|t=2020. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19.|pdf=|usr=008}} | ||
| + | {{tp|p=32475764|t=2020. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients.|pdf=|usr=008}} | ||
| + | |||
| + | ===Albumen=== | ||
| + | {{tp|p=32406952|t=2020. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.|pdf=|usr=008}} | ||
| + | {{tp|p=32456658|t=2020. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.|pdf=|usr=008}} | ||
| + | {{tp|p=32519791|t=2020. Hypoalbuminaemia in COVID-19 infection: A predictor of severity or a potential therapeutic target?|pdf=|usr=008}} | ||
| + | {{tp|p=32524832|t=2020. Is Albumin Predictor of Mortality in COVID-19?|pdf=|usr=008}} | ||
| + | |||
| + | |||
| + | ===Urine=== | ||
| + | {{tp|p=32484450|t=2020. Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19).|pdf=|usr=007}} | ||
| + | {{tp|p=32286242|t=2020. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019 |pdf=|usr=}} | ||
| + | |||
| + | ===ER stress=== | ||
| + | {{tp|p=32503824|t=2020. Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study.|pdf=|usr=007}} | ||
| + | |||
| + | ===autoantibodies=== | ||
| + | {{tp|p=32462425|t=2020. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.|pdf=|usr=008}} | ||
| + | |||
| + | ===MetHemoglobinemia=== | ||
| + | {{tp|p=32413176|t=2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.|pdf=|usr=007}} | ||
| + | |||
| + | ===profiling multiple parameters, reviews=== | ||
{{tp|p=32283164|t=ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China |pdf=|usr=}} | {{tp|p=32283164|t=ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China |pdf=|usr=}} | ||
{{tp|p=32324595|t=2020. The laboratory tests and host immunity of COVID-19 patients with different severity of illness |pdf=|usr=}} | {{tp|p=32324595|t=2020. The laboratory tests and host immunity of COVID-19 patients with different severity of illness |pdf=|usr=}} | ||
| Zeile 58: | Zeile 183: | ||
{{tp|p=C7107806|t=ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury |pdf=|usr=}} | {{tp|p=C7107806|t=ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury |pdf=|usr=}} | ||
{{tp|p=32452410|t=2020. Association of viral load with serum biomakers among COVID-19 cases |pdf=|usr=}} | {{tp|p=32452410|t=2020. Association of viral load with serum biomakers among COVID-19 cases |pdf=|usr=}} | ||
| + | {{tp|p=32503382|t=2020. Biomarkers associated with COVID-19 disease progression.|pdf=|usr=007}} | ||
| + | {{tp|p=32511971|t=2020. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.|pdf=|usr=007}} | ||
| + | {{tp|p=32508038|t=2020. Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia?|pdf=|usr=007}} | ||
| + | {{tp|p=32484453|t=2020. Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients.|pdf=|usr=007}} | ||
| + | {{tp|p=32441666|t=2020. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | ===host genetics=== | ||
| + | *[https://web.de/magazine/news/coronavirus/corona-neandertaler-gene-erhoehen-risiko-schweren-covid-19-verlauf-studie-35131364 Neandertaler-derived genes] [https://www.nature.com/articles/s41586-020-2818-3 original paper nature] | ||
| + | {{ttp|p=32404885|t=2020. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic.|pdf=|usr=008}} | ||
| + | {{tp|p=32393819|t=2020. COVID-19 outcomes and the human genome.|pdf=|usr=007}} | ||
| + | {{tp|p=32518411|t=2020. Genomic search for COVID-19 severity clues.|pdf=|usr=008}} | ||
| + | {{tp|p=32398162|t=2020. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission.|pdf=|usr=008}} | ||
| + | {{tp|p=32480226|t=2020. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.|pdf=|usr=008}} | ||
| + | {{tp|p=32405102|t=2020. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.|pdf=|usr=008}} | ||
| + | {{tp|p=32525600|t=2020. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.|pdf=|usr=008}} | ||
| + | {{tp|p=32416414|t=2020. Genetic predisposition models to COVID-19 infection |pdf=|usr=}} | ||
| + | |||
| + | |||
| + | '''blood groups''' | ||
| + | {{tp|p=32496734|t=2020. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.|pdf=|usr=007}} | ||
| + | {{tp|p=32453863|t=2020. COVID-19 and ABO blood group: another viewpoint.|pdf=|usr=007}} | ||
| + | {{tp|p=32513613|t=2020. COVID-19 and the ABO blood group connection.|pdf=|usr=008}} | ||
| + | {{tp|p=32343152|t=2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases |pdf=|usr=}} | ||
| + | |||
| + | '''HLA''' | ||
| + | {{tp|p=32303592|t=2020. Human leukocyte antigen susceptibility map for SARS-CoV-2 |pdf=|usr=}} | ||
| + | {{tp|p=32424945|t=2020. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19).|pdf=|usr=007}} | ||
| + | {{tp|p=32475052|t=2020. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | '''apoE''' | ||
| + | {{tp|p=32451547|t=2020. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort.|pdf=|usr=007}} | ||
| + | |||
| + | '''on ace2, trmpss2''' | ||
| + | {{tp|p=32430459|t=2020. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.|pdf=|usr=007}} | ||
| + | {{tp|p=32492195|t=2020. Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations.|pdf=|usr=007}} | ||
| + | {{tp|p=32501810|t=2020. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.|pdf=|usr=007}} | ||
| + | |||
| + | |||
| + | '''ace1''' | ||
| + | {{tp|p=32460534|t=2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.|pdf=|usr=007}} | ||
| + | |||
| + | '''complement''' | ||
| + | {{tp|p=32460534|t=2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.|pdf=|usr=007}} | ||
| + | {{tp|p=32517505|t=2020. C3 polymorphisms represent an important immunological confounder on the spread and outcome of COVID-19.|pdf=|usr=008}} | ||
| + | |||
| + | |||
| + | '''cytokines''' | ||
| + | {{tp|p=32490733|t=2020. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.|pdf=|usr=007}} | ||
| + | |||
| + | '''redox''' | ||
| + | {{tp|p=32454047|t=2020. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.|pdf=|usr=008}} | ||
Aktuelle Version vom 30. September 2020, 17:08 Uhr
any
32475810 2020. The role of biomarkers in diagnosis of COVID-19 - A systematic review.
32259132 2020. Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study
32360478 2020. Emerging key laboratory tests for patients with COVID-19
32371192 ä. Using the diagnostic model based on routine laboratory tests to distinguish patients infected with SARS-CoV-2 from those infected with influenza virus
32344011 2020. Mild versus severe COVID-19: Laboratory markers
32341519 ä. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia
32301748 2020. Clinical chemistry tests for patients with COVID-19 - important caveats for interpretation
32526372 2020. Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests.
32425643 2020. Association of inflammatory markers with the severity of COVID-19: A meta-analysis.
32519779 2020. Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms.
32471703 2020. Laboratory Biomarkers Predicting COVID-19 Severity in the Emergency Room.
32492406 2020. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera.
Hypoxia
32471783 2020. Silent hypoxia: A harbinger of clinical deterioration in patients with COVID-19.
Glucose
32360710 2020. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes
32515386 2020. Glucovigilance in COVID-19.
Presepsin
32333860 2020. Presepsin in risk stratification of SARS-CoV-2 patients
32530491 2020. Presepsin as a predictive biomarker of severity in COVID-19: A case series.
Procalcitonin
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32414743 2020. Procalcitonin for patient stratification and identification of bacterial co-infection in COVID-19.
32534186 2020. Procalcitonin levels in COVID-19 patients.
SAA serum amyloid a
32277967 ä. SAA is a biomarker to distinguish the severity and prognosis of Coronavirus Disease 2019 (COVID-19)
suPAR
32354367 2020. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia
Fever
32503659 2020. Body temperature correlates with mortality in COVID-19 patients.
32417316 2020. Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19.
32519768 2020. Hyperpyrexia in COVID-19 patients.
ESR BKS BSG
32386190 2020. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis.
CRP
32368728 ä. Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32281668 2020. C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early
32455147 ä. C reactive protein level may predict the risk of COVID-19 aggravation
32511972 2020. C-reactive protein: A promising biomarker for poor prognosis in COVID-19 infection.
32445579 2020. Prognostic value of C-reactive protein in patients with COVID-19.
32425269 2020. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.
32516845 2020. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19.
32414383 2020. Plasma CRP level is positively associated with the severity of COVID-19.
32531257 2020. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.
32533986 2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.
IL-6
32344321 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19
32259560 ä. Interleukin-6 as a potential biomarker of COVID-19 progression
32414693 2020. Interleukin-6 levels in children developing SARS-CoV-2 infection
32297995 2020. High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients
32475230 2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
32428990 2020. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.
32385523 2020. IL-6 may be a good biomarker for earlier detection of COVID-19 progression.
32425269 2020. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19.
32526326 2020. Interleukin-6 as prognosticator in patients with COVID-19.
IL-10
32475230 2020. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
32501293 2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.
IL-1ra
32501293 2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.
Rantes
32501293 2020. Longitudinal COVID-19 profiling associates IL-1Ra and IL-10 with disease severity and RANTES with mild disease.
NLratio
32283162 ä. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19
32242828 2020. Decreased "WBC*LYM" was observed in SARS-CoV-2-infected patients from a fever clinic in Wuhan
32458459 2020. Neutrophil to lymphocyte ratio as prognostic and predictive factor in patients with coronavirus disease 2019: A retrospective cross-sectional study.
32304994 ä. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients
32503668 2020. Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.
32242950 2020. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis.
32533986 2020. Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis.
32531713 2020. Neutrophil to CD4+ lymphocyte ratio as a potential biomarker in predicting virus negative conversion time in COVID-19.
32437920 2020. Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line.
PLratio
32181903 2020. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.
Troponin
32348472 ä. A Marker of Systemic Inflammation or Direct Cardiac Injury: Should Cardiac Troponin Levels be Monitored in COVID-19 Patients?
Eosinophils
| 32315429 ä. Eosinophil count in severe coronavirus disease 2019 (COVID-19) |
32315421 ä. Response letter to Eosinophil count in severe coronavirus disease 2019 (COVID-19)
IL2R on lymphcytes
32365221 2020. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19
Angiopoietin 2
32458111 2020. Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients.
microRNA
32526370 2020. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?
tumor markers
32347972 2020. Elevations of serum cancer biomarkers correlate with severity of COVID-19
mda5 il-24
32485313 2020. MDA5 should be detected in severe COVID-19 patients.
H2S
32433216 2020. Serum Hydrogen Sulfide and Outcome Association in Pneumonia by the SARS-CoV-2 Corona virus.
ACE2
32283335 2020. ACE2, COVID19 and serum ACE as a possible biomarker to predict severity of disease.
trmpss2
32437018 2020. TMPRSS2: Potential Biomarker for COVID-19 Outcomes.
KL-6
32470148 2020. Serum KL-6 concentrations as a novel biomarker of severe COVID-19.
monocyte distribution width
32504637 2020. Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator.
Calcium
32459190 2020. Low levels of total and ionized calcium in blood of COVID-19 patients.
32533508 2020. Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19.
LDH
32531257 2020. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients.
Liver enzymes
32525000 2020. Aspartate aminotransferase: A prognostic marker rather than a specific liver injury marker in COVID-19.
32526083 2020. Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19.
32475764 2020. An updated meta-analysis of AST and ALT levels and the mortality of COVID-19 patients.
Albumen
32406952 2020. Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity.
32456658 2020. The association of low serum albumin level with severe COVID-19: a systematic review and meta-analysis.
32519791 2020. Hypoalbuminaemia in COVID-19 infection: A predictor of severity or a potential therapeutic target?
32524832 2020. Is Albumin Predictor of Mortality in COVID-19?
Urine
32484450 2020. Urinalysis parameters for predicting severity in coronavirus disease 2019 (COVID-19).
32286242 2020. The value of urine biochemical parameters in the prediction of the severity of coronavirus disease 2019
ER stress
32503824 2020. Endoplasmic Reticulum Stress Markers in SARS-COV-2 Infection and Pneumonia: Case-Control Study.
autoantibodies
32462425 2020. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.
MetHemoglobinemia
32413176 2020. The emergence of methemoglobinemia amidst the COVID-19 pandemic.
profiling multiple parameters, reviews
32283164 ä. Clinical and laboratory-derived parameters of 119 hospitalized patients with coronavirus disease 2019 in Xiangyang, Hubei Province, China
32324595 2020. The laboratory tests and host immunity of COVID-19 patients with different severity of illness
32301746 2020. Routine blood tests as a potential diagnostic tool for COVID-19
32119647 2020. Laboratory abnormalities in patients with COVID-2019 infection
32172227 2020. Laboratory abnormalities in children with novel coronavirus disease 2019
| 32286245 2020. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis |
32181911 ä. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID?19
C7107806 ä. Elevated levels of plasma cytokines in COVID-19 reflect viral load and lung injury
32452410 2020. Association of viral load with serum biomakers among COVID-19 cases
32503382 2020. Biomarkers associated with COVID-19 disease progression.
32511971 2020. Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.
32508038 2020. Can routine laboratory tests discriminate SARS-CoV-2-infected pneumonia from other causes of community-acquired pneumonia?
32484453 2020. Infection with SARS-CoV-2 causes abnormal laboratory results of multiple organs in patients.
32441666 2020. Dynamic profile and clinical implications of hematological parameters in hospitalized patients with coronavirus disease 2019.
host genetics
| 32404885 2020. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. |
32393819 2020. COVID-19 outcomes and the human genome.
32518411 2020. Genomic search for COVID-19 severity clues.
32398162 2020. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission.
32480226 2020. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.
32405102 2020. A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection.
32525600 2020. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.
32416414 2020. Genetic predisposition models to COVID-19 infection
blood groups
32496734 2020. The effects of blood group types on the risk of COVID-19 infection and its clinical outcome.
32453863 2020. COVID-19 and ABO blood group: another viewpoint.
32513613 2020. COVID-19 and the ABO blood group connection.
32343152 2020. ABO blood group predisposes to COVID-19 severity and cardiovascular diseases
HLA
32303592 2020. Human leukocyte antigen susceptibility map for SARS-CoV-2
32424945 2020. Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease-2019 (COVID-19).
32475052 2020. Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide.
apoE
32451547 2020. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort.
on ace2, trmpss2
32430459 2020. Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits.
32492195 2020. Functional prediction and frequency of coding variants in human ACE2 at binding sites with SARS-CoV-2 spike protein on different populations.
32501810 2020. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy.
ace1
32460534 2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.
complement
32460534 2020. C3 and ACE1 polymorphisms are more important confounders in the spread and outcome of COVID-19 in comparison with ABO polymorphism.
32517505 2020. C3 polymorphisms represent an important immunological confounder on the spread and outcome of COVID-19.
cytokines
32490733 2020. Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans.
redox
32454047 2020. An evidence for correlation between the glutathione S-transferase T1 (GSTT1) polymorphism and outcome of COVID-19.
